Metraipolis › archive › dc_73d8ebc8ddde

Neoadjuvant FOLFOXIRI plus bevacizumab without radiotherapy for high-risk rectal cancer: multicentre phase II trial — Europe PMC PMID:41661200

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41661200
DOI: 10.1093/bjsopen/zraf163
License (as archived): solo-consultazione
Archived: 2026-11-08T02:56:20.730Z
SHA-256 of the archived text: 366732e41a399a813d805f8e8f3370cbbf6bd488f88a192426909a268f90ed6d
Stable URL of this page: https://metraipolis.com/documento/dc_73d8ebc8ddde

How to cite

Neoadjuvant FOLFOXIRI plus bevacizumab without radiotherapy for high-risk rectal cancer: multicentre phase II trial — Europe PMC PMID:41661200 — Europe PMC (en), https://europepmc.org/article/MED/41661200 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_73d8ebc8ddde (Metraipolis archive dc_73d8ebc8ddde, sha256 366732e41a399a813d805f8e8f3370cbbf6bd488f88a192426909a268f90ed6d)

BibTeX

@misc{dc73d8ebc8ddde,
  title = {Neoadjuvant FOLFOXIRI plus bevacizumab without radiotherapy for high-risk rectal cancer: multicentre phase II trial — Europe PMC PMID:41661200},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41661200},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_73d8ebc8ddde; sha256 366732e41a399a813d805f8e8f3370cbbf6bd488f88a192426909a268f90ed6d},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41661200. Agents can read the archived copy with the MCP tool read_document.